Figure 5.
Figure 5. EBV–T-cell line cytotoxicity against autologous LCL in controls and XLP patients. Cytotoxicity of untransduced and transduced EBV–T-cell lines from controls and XLP patients was measured using LDH release assays. (A) EBV–T-cell lines from C1 untransduced (CTLC1), eGFP/SAP-vector transduced (S + CTLC1), and eGFP alone vector (G + CTLC1); (B) the same as for panel A, except using CTLC2; (C) the same as for panel A, except using CTLP1; (D) the same as for panel A, except using CTLP2. (E) Incubation of eGFP/SAP vector–transduced EBV–T-cell lines from both controls and XLP patients (S + CTLC1, S + CTLC2, S + CTLP1, S + CTLP2) with W6/32 antibody.

EBV–T-cell line cytotoxicity against autologous LCL in controls and XLP patients. Cytotoxicity of untransduced and transduced EBV–T-cell lines from controls and XLP patients was measured using LDH release assays. (A) EBV–T-cell lines from C1 untransduced (CTLC1), eGFP/SAP-vector transduced (S + CTLC1), and eGFP alone vector (G + CTLC1); (B) the same as for panel A, except using CTLC2; (C) the same as for panel A, except using CTLP1; (D) the same as for panel A, except using CTLP2. (E) Incubation of eGFP/SAP vector–transduced EBV–T-cell lines from both controls and XLP patients (S + CTLC1, S + CTLC2, S + CTLP1, S + CTLP2) with W6/32 antibody.

Close Modal

or Create an Account

Close Modal
Close Modal